Summary: A new study trial leveraged objective biological and behavioral markers to predict drug efficacy. By screening patients using a combination of functional MRI (fMRI) brain connectivity networks, cognitive reward sensitivity, and clinical profiles, researchers successfully predicted patient outcomes.
Patients possessing favorable biomarker signatures achieved a 71.4% treatment response rate, marking an approximate 67% increase over those lacking these biological indicators.
Key Facts
- The Clinical Trial-and-Error Burden: Only 30% to 50% of individuals with major depression respond favorably to their initial antidepressant selection. The traditional trial-and-error method routinely burns through weeks or months of a patient’s life, a dangerous latency period during which underlying symptoms can compound.
- The Dual-Medication Predictor: The study is among the first to validate biomarker-guided antidepressant selections utilizing two distinct, widely used medications: sertraline (which increases serotonin) and bupropion (which targets norepinephrine and dopamine).
- The Algorithmic Codebook: Drawing data from the landmark national EMBARC study, the research team constructed predictive algorithms. The models seamlessly cross-reference functional MRI (fMRI) brain connectivity data with cognitive control testing, reward sensitivity metrics, personality traits, and baseline life variables like employment status.
- The 67% Response Jump: When tested prospectively, patients identified with positive biological markers for both medications experienced a massive 71.4% response rate. In stark contrast, individuals who presented zero positive biomarker indicators saw their response rates plummet to 42.8%.
- Depression Is Not Uniform: Dr. Pizzagalli stresses that this study delivers clear, empirical proof that depression is not a single uniform disease. Rather, it is a umbrella condition driven by entirely different biological pathways depending on the individual, explaining why a drug that saves one life fails in another.
- Clinical Horizon & Fast-Tracking Alternative Care: While the tool is not yet ready for immediate, daily clinic deployment due to a small final analytical sample (fewer than 50 patients) and the high costs of fMRI scans, it provides an invaluable framework. In the future, identifying patients lacking these markers early will allow doctors to bypass standard pills completely, fast-tracking them directly to advanced options like ketamine, brain stimulation therapy (TMS), or intensive psychotherapy.
Source: UC Irvine
For decades, treating depression has largely involved a difficult form of medical guesswork: prescribing one antidepressant after another in hopes that one will eventually help.
A new study led by researchers at the University of California, Irvine and Mass General Brigham-affiliated McLean Hospital suggests that psychiatry may be moving toward something far more precise.
Published today in Nature Mental Health, the study found that using biological and behavioral markers to guide antidepressant treatment selection boosted response rates by nearly 67 percent compared with patients who lacked favorable biomarker profiles.
Researchers said it was one of the first studies to test biomarker-guided antidepressant treatment selection in patients with major depressive disorder using two widely prescribed medications.
Diego A. Pizzagalli, founding director of UC Irvine’s Noel Drury, M.D. Institute for Translational Depression Discoveries and Distinguished Professor of psychiatry and human behavior, neurobiology and behavior, and biomedical engineering, led the effort.
“Depression treatment still relies far too heavily on trial and error,” Pizzagalli said. “Patients often spend months cycling through medications before finding one that works, while symptoms worsen and suicide risk can increase. Our findings suggest we may be able to move psychiatry closer to precision medicine, where objective biological and behavioral data help guide treatment decisions from the outset.”
The challenge is enormous. Major depressive disorder affects hundreds of millions of people worldwide, yet only 30 to 50 percent of patients respond to the first antidepressant treatment. Even when medications eventually work, individuals may endure weeks or months of debilitating symptoms, side effects and uncertainty before improvement begins.
Unlike many other fields of medicine, psychiatry still lacks objective laboratory tests or biomarkers that can reliably guide treatment decisions, Pizzagalli said.
To address that gap, the researchers turned to two of the most commonly prescribed antidepressants: sertraline, sold under the brand name Zoloft, and bupropion, sold as Wellbutrin.
Using data from a large national depression study known as EMBARC, in a first step, investigators developed predictive algorithms based on a combination of brain imaging, cognitive testing and clinical characteristics. The models incorporated factors including functional MRI measurements of brain connectivity, reward sensitivity, cognitive control, depression severity, personality traits and employment status.
In a separate study, the researchers used these predictive algorithms to select which antidepressant should be prescribed for each participant with major depressive disorder. Specifically, subjects underwent brain imaging, cognitive testing and psychiatric assessments before being assigned to receive either sertraline or bupropion based on the algorithms developed in the prior study.
One of the study’s most striking findings emerged when researchers examined overall biomarker patterns. Patients with favorable biomarkers for one or both medications responded substantially better than patients with no positive biomarkers.
Response rates reached 71.4 percent among patients with positive biomarkers for both medications, compared with 42.8 percent among patients with no positive biomarkers – a nearly 67 percent improvement.
The study did not find statistically significant differences between patients who received the medication specifically matched to their biomarker profile and those intentionally assigned a nonmatching medication, likely because a larger sample size will be necessary to test this hypothesis. But researchers said the broader pattern still offers notable evidence that measurable biological signatures may help identify patients more apt to benefit from standard antidepressants.
“This is important because it reinforces the idea that depression is not a single uniform illness,” Pizzagalli said. “Different biological pathways likely contribute to symptoms in different people. Understanding those differences could eventually allow us to tailor treatments much more effectively.”
The implications could extend well beyond medication selection. In the future, biomarker-guided approaches might help clinicians identify patients unlikely to respond to conventional antidepressants, allowing them to move more quickly toward alternatives such as psychotherapy, brain stimulation therapies or ketamine-based treatments.
Researchers cautioned that the technology is not yet ready for routine clinical use. The study involved fewer than 50 patients in the final analyses, and some predictive measures relied on expensive functional MRI scans that are not, to date, practical for most clinical settings.
Still, scientists said the work represents a milestone in the emerging field of precision psychiatry – an effort to bring the kind of personalized treatment strategies now common in cancer care and cardiology into mental health treatment.
“This study is an early but important proof of concept,” Pizzagalli said. “It lays the groundwork for larger studies that could ultimately transform how we treat depression. These are the types of studies that we will prioritize within the recently launched Noel Drury, M.D. Institute for Translational Depression Discoveries at UC Irvine.”
The research was conducted at McLean Hospital in collaboration with investigators from UC Irvine.
Funding: The National Institute of Mental Health funded the EMBARC study. The UC Irvine-led clinical trial received support from Wellcome Leap’s Multi-Channel Psych program. Pizzagalli also received partial backing from the National Institute of Mental Health.
Key Questions Answered:
A: Unlike other fields of medicine, like cardiology or oncology, where doctors use blood tests, EKGs, or tumor biopsies to pick the perfect treatment, psychiatry currently lacks objective laboratory tests. Doctors have to rely almost entirely on subjective diagnostic interviews and symptom checklists. Because major depression can look identical on the outside but be caused by completely different biological pathways on the inside, a pill that works wonders for one person might fail completely for another, turning treatment into a slow process of medical guessing.
A: The research team at UC Irvine and McLean Hospital built predictive computer algorithms by pulling data from a massive national depression study called EMBARC. Instead of looking at just one metric, the system evaluates a multi-layer profile of the patient’s brain and life. It analyzes functional MRI scans to map brain connectivity, runs cognitive tests to measure how sensitive the patient is to rewards and mental control, and inputs personal traits like depression severity and employment status. By combining these biological and behavioral markers, the algorithm can spot the hidden signatures of who is most likely to improve on a specific medication.
A: While this study is a massive milestone and a brilliant proof of concept, the technology is not quite ready for your local doctor’s office yet. The final phase of this initial trial analyzed a very small group of fewer than 50 patients, meaning researchers must run much larger clinical trials to fully confirm the algorithm’s accuracy. Furthermore, the system currently requires expensive functional MRI brain scans, which are not accessible or affordable for most neighborhood mental health clinics. However, the newly launched Noel Drury, M.D. Institute at UC Irvine is actively prioritizing these exact studies to scale this technology and make it practical and affordable for everyone.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this psychopharmacology and mental health research news
Author: Carly Murphy
Source: University of California – Irvine
Contact: Carly Murphy – University of California – Irvine
Image: The image is credited to Neuroscience News
Original Research: Open access.
“A precision medicine trial of bupropion and sertraline for major depressive disorder using a biomarker-guided sequential multiple-assignment design” by Peter Zhukovsky, Manuel Kuhn, Lauren R. Borchers, Boyu Ren, Sarah E. Woronko, Mohan Li, Choi Sze Tracy Lam, Ethan M. Zhang, Kerry J. Ressler, Brian P. Brennan, Gordana Vitaliano & Diego A. Pizzagalli. Nature Mental Health
DOI:10.1038/s44220-026-00671-z
Abstract
A precision medicine trial of bupropion and sertraline for major depressive disorder using a biomarker-guided sequential multiple-assignment design
Treatment for major depressive disorder (MDD) remains challenging as only 30–50% of patients respond to first-line antidepressant medications in primary care.
Here we developed algorithms using predictors of response to sertraline and bupropion from a multisite study, and tested such markers in an independent, prospective clinical trial involving unmedicated individuals with MDD (NCT05537584). Leave-one-out cross-validation models achieved good performance in the training sample (area under the curve of 0.66–0.86).
In the preregistered clinical trial, no significant differences in treatment outcomes emerged for those assigned a drug consistent versus inconsistent with their biomarkers. However, significant differences emerged in symptom reduction trajectories for those with positive markers for both medications (response rate: 71.4%) or either drug (65.4%) compared with those with two negative markers (42.9%).
This is the first study using biobehavioral markers to prospectively guide assignment to two widely used antidepressants, yielding a 66.8% boost in response rate and providing foundations for larger personalized treatment studies of MDD.
